Filing Flows › Avita Medical (RCEL) › Q3 2026 › vs Q3 2025
Avita Medical (RCEL) Q3 2026 vs Q3 2025 (year over year)
Avita Medical's revenue rose $9.1M (+53%) from $17.1M in Q3 2025 to $26.1M in Q3 2026.
Avita Medical, Q3 2026: revenue $26.1M (+53% year over year), operating margin -10.1%, net loss $6.2M, operating cash flow −$710K. The chart draws each line against Q3 2025, the increases inside each band.
Every line
| Line | Q3 2026 | Q3 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $26.1M | $17.1M | $9.1M | +53% |
| Net loss | $6.2M | $13.2M | −$7.0M | -53% |
| Costs & expenses | $32.3M | $30.2M | $2.1M | +7% |
| Operating costs | $28.7M | $26.2M | $2.5M | +10% |
| Interest & other, net | $3.5M | $4.0M | −$491K | -12% |
| Income tax | $65K | $15K | $50K | +333% |
| Cost of revenue | $4.2M | $3.2M | $986K | +31% |
| Research & development | $4.7M | $3.7M | $949K | +25% |
| Sales & marketing | $13.6M | $12.1M | $1.5M | +13% |
| General & admin | $6.3M | $7.2M | −$920K | -13% |
| Operating cash sources | $6.2M | $13.2M | −$7.0M | -53% |
| Depreciation & amortization | $592K | $574K | $18K | +3% |
| Share-based compensation | $1.7M | $2.8M | −$1.1M | -40% |
| Working capital & other | $3.3M | $4.6M | −$1.4M | -30% |
| Cash used in operations | $710K | $5.2M | −$4.5M | -86% |
| Net loss absorbed | $6.2M | $13.2M | −$7.0M | -53% |
Questions
How much did Avita Medical's revenue grow year over year in Q3 2026?
Avita Medical's revenue rose $9.1M (+53%) from $17.1M in Q3 2025 to $26.1M in Q3 2026.